Tick Boot Camp

Matt Sabatello and Rich Johannesen
  • 0.0 (0)
  • ALTERNATIVE HEALTH
  • UPDATED WEEKLY

The goal of the Tick Boot Camp Podcast is to help people liberate themselves and others from suffering caused by Lyme disease through validation, community building, belief that healing is possible, and modeling success. Listen to our Tick Boot Camp podcast using all major podcast streaming services such as Apple Podcasts, Spotify, and YouTube Music. Our podcast is also integrated with smart home devices, such as Amazon Alexa and Apple TV. Ask your device to "play the Tick Boot Camp Podcast!"

  1. 18 HR AGO

    Persistent Infection, Molecular Mimicry, and the Future of Chronic Lyme | Amy Proal, PhD

    In this powerful and science-forward episode of the Tick Boot Camp Podcast, host Matt Sabatello sits down with Amy Proal, PhD, a leading microbiologist whose work is reshaping how the medical community understands chronic Lyme disease, post-treatment Lyme disease (PTLD), ME/CFS, and Long COVID. Dr. Proal brings a rare combination of deep scientific expertise, lived experience with chronic illness, and real-world clinical integration, offering listeners clarity on why so many patients remain sick long after standard treatment ends — and what science is finally doing about it. 👩‍🔬 About Amy Proal, PhD Amy Proal, PhD, is an internationally recognized microbiologist specializing in the molecular mechanisms by which persistent pathogens alter human immunity, metabolism, and gene expression. She currently serves in two major leadership roles: President & Research Director, PolyBio Research Foundation Scientific Director, Cohen Center for Recovery from Complex Chronic Illness (CORE) at Mount Sinai Her work focuses on infection-associated chronic illness, including: Chronic Lyme disease & tick-borne co-infections Post-treatment Lyme disease syndrome (PTLD) ME/CFS Long COVID Dr. Proal is widely known for helping shift the scientific narrative away from psychosomatic explanations and toward biological root causes driven by persistent infection and immune dysregulation. 🧬 PolyBio Research Foundation: Rewriting the Science of Chronic Illness Dr. Proal co-founded PolyBio Research Foundation in 2018 alongside neuroscientist Dr. Michael VanElzakker, after recognizing that most chronic illness research ignored root cause biology, particularly infection. What Makes PolyBio Different Led by scientists, not administrators Focused on tissue-based research, not just blood tests Actively recruits researchers from HIV, tuberculosis, and virology fields to study Lyme and ME/CFS Designs research programs before fundraising, ensuring scientific rigor PolyBio has played a major role in advancing research on: Pathogen persistence in human tissue Hidden reservoirs of infection Why standard diagnostics often fail 🏥 Cohen Center for Recovery from Complex Chronic Illness (CORE) Dr. Proal also serves as Scientific Director of the Cohen Center for Recovery from Complex Chronic Illness (CORE) at Mount Sinai in New York City. CORE’s Mission Treat patients with Long COVID and chronic tick-borne illness within an insurance-based system Integrate clinical care with active research and clinical trials Establish new standards of care for infection-associated chronic disease At CORE, Dr. Proal helps design studies that leverage real patient visits — asking critical questions such as: Where is the pathogen hiding? What tissues are affected? What immune pathways are disrupted? 🧠 Persistent Infection & Why Blood Tests Fail A central theme of the episode is that chronic infection is often a tissue-based disease, not a blood-based one. Dr. Proal explains: Pathogens like Borrelia (Lyme) and SARS-CoV-2 actively avoid the bloodstream Blood is heavily patrolled by immune cells — tissue offers protection Absence of evidence in blood ≠ absence of infection This helps explain why: Lyme disease often goes undetected by standard serology Patients remain symptomatic despite “negative tests” Tissue biopsies and advanced imaging are essential for progress 🧬 Molecular Mimicry: How Infection Triggers Autoimmune Symptoms Dr. Proal provides a clear explanation of molecular mimicry, a key mechanism linking infection and autoimmunity. What Is Molecular Mimicry? Pathogens produce proteins that closely resemble human proteins The immune system attacks the pathogen — and accidentally attacks the body This creates autoimmune-like disease, even though infection is the trigger This mechanism helps explain: Why immune suppression may reduce symptoms but worsen disease Why many autoimmune diagnoses may actually be infection-driven Why treating the pathogen matters, not just calming the immune system 🔁 Successive Infection: Why Some Patients Get Sicker Than Others A major insight from this episode is Dr. Proal’s concept of successive infection. Rather than genetics alone, she suggests severity is often driven by: Prior infections (Lyme, Bartonella, Babesia, viruses) Environmental exposures (mold, toxins) Physical trauma (concussions, brain injury) Each “hit” dysregulates the immune system, making the next infection harder to clear — a cumulative burden that explains why: Some people become severely ill from Lyme Others remain asymptomatic despite repeated tick exposure 🧠 Neurological Lyme, the Brain & the Vagus Nerve Dr. Proal discusses multiple ways Lyme and infections affect the nervous system: Direct CNS Infection Pathogens crossing the blood–brain barrier Microglial activation causing neuroinflammation Indirect Neurological Signaling Infection in the gut, heart, or lungs activating the vagus nerve nearby Direct infection of the vagus nerve with Lyme Brainstem signaling triggering fatigue, pain, dysautonomia, and brain fog This dual-pathway model explains why neurological symptoms can occur even without detectable brain infection. 🧫 Tissue, Imaging & the Future of Diagnostics One of the most exciting parts of the episode covers next-generation diagnostics, including: Tissue biopsies (gut, lymph nodes, nerve, synovium) Ultra-sensitive molecular detection Immune cell exhaustion markers (e.g., PD-1) Advanced imaging that can map pathogens in the body Dr. Proal explains how future tools may: Identify not just presence , but activity of infection Distinguish nervous system involvement Enable targeted clinical trials and personalized treatment 🧠 Infection, Alzheimer’s & Neurodegenerative Disease Dr. Proal also discusses compelling research linking infection to Alzheimer’s disease, including evidence that: Amyloid plaques may be part of the innate immune response Plaques form around viral, bacterial, and fungal pathogens Removing amyloid alone fails because it ignores root cause This framework aligns with decades of overlooked research connecting Lyme, herpesviruses, and neurodegeneration. 🌱 Hope for the Lyme & Chronic Illness Community Dr. Proal closes the episode with optimism, highlighting: Rapid advances in diagnostics Better-designed clinical trials Increasing collaboration across institutions A long-overdue shift toward biological validation Her message is clear: Patients were right. Science is finally catching up. 🔑 Key Topics Covered Chronic Lyme disease Post-treatment Lyme disease syndrome (PTLD) Persistent Borrelia infection Molecular mimicry and autoimmunity Successive infection model Long COVID pathogen persistence Tissue-based diagnostics Neurological Lyme disease Vagus nerve and dysautonomia Cohen Center for Recovery from Complex Chronic Illness PolyBio Research Foundation

    1h 33m

  2. 7 MAR

    The Stanford Scientist Rewriting the Future of Lyme Disease Treatment — Dr. Jayakumar Rajadas | Tick Boot Camp

    In this groundbreaking episode of the Tick Boot Camp Podcast, we interview Dr. Jayakumar Rajadas, a Stanford Medicine researcher who has discovered multiple breakthrough therapeutic candidates for Lyme disease, Babesia, and Bartonella. His work includes the discovery of Disulfiram’s effectiveness against Lyme and Babesia, Azlocillin’s potent activity against Lyme and Bartonella, and advanced targeted drug-delivery systems designed to preserve the gut microbiome. Dr. Jay's research has been featured in TIME Magazine (Azlocillin) and Forbes (Disulfiram), and connects deeply with the work of leading Lyme researchers, including Dr. Monica Embers (Tulane), Dr. Kim Lewis (Northeastern), Dr. Kenneth Liegner, and Dr. Brian Fallon (Columbia University). This interview delivers hope, science, and unprecedented detail on what may become the next generation of Lyme disease treatments. Key Topics Covered 1. How the Stanford Tick Initiative Sparked a New Era of Drug Discovery In 2012, Stanford launched a major initiative in response to community demand for better Lyme treatments. Dr. Rajadas was selected to lead drug development, focusing specifically on persistent/chronic Lyme disease, where few researchers were working. 2. Understanding Borrelia: Active vs. Stationary Forms & Why Chronic Lyme Persists Dr. J explains the three key survival modes of Borrelia burgdorferi: Active Phase The bacteria are replicating and metabolically active. Easier to kill with standard antibiotics. Stationary Phase Bacteria reach population limits and slow down growth. Represents early persistence mechanisms. Persister Forms Triggered by stressors like antibiotics (e.g., doxycycline). Bacteria fold into round bodies, spiral forms, or compact “cement-like” protective balls. These forms: Shut down metabolic pathways Resist penetration Survive antibiotic exposure Why Doxycycline Can Fail Doxycycline can induce persisters, causing Borrelia to form impenetrable protective shells rather than die. This is why many patients initially feel better, then relapse. 3. Disulfiram (Antabuse): Lyme + Babesia Breakthrough Featured in Forbes One of the biggest scientific shocks of the last decade: Discovery Through Stanford’s high-throughput screening of FDA-approved drugs, Disulfiram emerged as a top hit. Clears Borrelia (including persistent forms) Clears Babesia — a major advantage over standard antibiotics Does NOT harm the gut microbiome Is already FDA-approved and widely used for alcohol aversion therapy Highly potent but requires careful dosing due to side effects in inflamed patients. Why Some Patients Improve, and Others Suffer Chronic Lyme patients already have heightened inflammation. Disulfiram is a powerful molecule whose polymorphic forms behave differently in different people. His lab developed: Less toxic formulations Buccal & sublingual delivery systems Rectal delivery options These may reduce neuropsychiatric side effects reported by some patients. Clinical Connections Dr. Kenneth Liegner pioneered clinical use and published cases Dr. Brian Fallon conducted NIH-listed clinical trials. Many clinicians now use Liegner’s protocols. Real-world example: Matt shares the story of Brooke Stoddard (Generation Lyme), who regained his life after Disulfiram treatment under Dr. Liegner. 4. Azlocillin: The Antibiotic That TIME Magazine Called a Gamechanger If Disulfiram is the Lyme and Babesia weapon, Azlocillin may be the frontline tool for Lyme and Bartonella. Why Azlocillin Is Revolutionary Eradicates both active and persister forms of Borrelia. Destroys doxycycline-induced “cement ball” persisters by drilling into their vulnerable cell-wall synthesis pathways. Proven effective against Bartonella when paired with azithromycin, based on research by Dr. Monica Embers (Tulane) . The Cell-Wall Vulnerability Breakthrough Persisters STILL must maintain minimal cell-wall synthesis to survive. Azlocillin exploits this tiny vulnerability: It penetrates the protective sphere Breaks the “cement wall” Forces the bacteria out of hibernation Kills them rapidly This discovery is one of the biggest scientific leaps in Lyme research in a decade. The Delivery System That Protects the Gut Microbiome Azlocillin is extremely hydrophilic, making absorption difficult.Dr. Jay fixed this by creating: A magnesium-lipid nanoparticle formulation Designed to release in the upper intestine Avoiding the colon (where most microbiome lives) This allows: High bloodstream absorption Minimal microbiome damage Oral availability of a drug previously only available via IV Why Azlocillin May Be Better Than Disulfiram Hits Borrelia + Bartonella Stronger anti-inflammatory effects No polymorphism issues Fewer side effects Potent against persisters A company is preparing to bring his oral formulation to clinical trials by next year. 5. Loratadine (Claritin): The First Clue from 2012 Before Disulfiram and Azlocillin, Dr. Jay’s lab identified Loratadine (Claritin) as a manganese transporter inhibitor of Borrelia. Why it mattered: Borrelia uniquely relies on manganese, not iron. Blocking manganese uptake may weaken the bacteria. The discovery went viral, with many patients reporting improvement even at OTC doses—though the binding affinity was weak. This project introduced the concept of drug repurposing for Lyme to the scientific community. 6. Melittin (Bee Venom) — The Micro-Needle Patch Alternative Bee venom therapy is widely used in the Lyme community, but risks stings and allergic reactions. Dr. J is developing: Melittin micro-needle patches Delivering the active peptide without stinging Using dissolvable, painless needles A safe, controlled, pharmaceutical-grade delivery approach This could modernize bee venom therapy and make it more accessible. 7. Mechanism of Brain Fog & Fatigue in Lyme: A Major Breakthrough Dr. Jay’s lab published a neuroscience paper demonstrating: Outer Surface Protein (Osp) Nanoparticles Borrelia sheds lipid-coated outer membrane particles. These form stable nano-vesicles that: Enter the bloodstream Cross into the brain Cause mitochondrial dysfunction Reduce ATP production Result: Brain Fog, Fatigue, Cognitive Dysfunction This explains why neurological Lyme can persist even after bacterial levels drop. This work ties strongly to ongoing research at Columbia University under Dr. Brian Fallon. 8. Collaborations With World Leaders in Lyme Research Dr. J’s research intersects with: Dr. Kim Lewis (Northeastern University) Reproduced and validated Disulfiram findings publicly. Helped launch interest in persister-killing therapies. Dr. Monica Embers (Tulane University) Demonstrated Azlocillin + Azithromycin effectiveness against Bartonella. One of the world’s foremost experts in persistent infection models. Dr. Kenneth Liegner Early clinical pioneer of Disulfiram therapy. Published stunning recovery cases. Dr. Brian A. Fallon (Columbia University) Leading psychiatrist specializing in post-treatment Lyme. Conducted planned Disulfiram clinical trials. These collaborations form a powerful network accelerating treatment development. 9. New Anti-Inflammatory Discoveries: Galangin & More Dr. Jay recently co-authored a 2025 paper on: Galangin (Thai ginger rhizome extract) Which may reverse cardiac inflammation and fibrosis His team is also exploring other nutraceutical molecules for chronic inflammation relief in Lyme patients. 10. Dr. Jay’s Personal Story of Illness and Hope He reveals for the first time: He was diagnosed with Stage 3 Multiple Myeloma Lost the ability to walk Suffered unbearable pain After cutting-edge therapies and research, he is now in full remission His message to Lyme patients: “There is ALWAYS hope.”

    1h 30m

  3. 28 FEB

    Solving Lyme Diagnostics and Discovering New Tick-Borne Pathogens with Dr. Bobbi S. Pritt

    Dr. Bobbi S. Pritt joins Tick Boot Camp Podcast for a scientific deep dive into Lyme disease diagnostics, co-infections, and emerging tick-borne pathogens. Dr. Pritt is Professor and Chair of Laboratory Medicine and Pathology at Mayo Clinic and Director of the Clinical Parasitology Laboratory in Rochester, Minnesota. An internationally recognized expert in vector-borne diseases, she is globally known for discovering new tick-borne pathogens—including Borrelia mayonii and Ehrlichia muris eauclairensis—and for advancing cutting-edge molecular and metagenomic diagnostic testing used nationwide. This episode offers essential clarity for anyone navigating Lyme disease, unexplained symptoms, or confusing test results. Dr. Pritt explains why standard tests often miss early Lyme, how PCR and molecular tools can detect active infection, and what metagenomic sequencing may offer for more accurate and comprehensive diagnostics in the future. Episode Summary Dr. Pritt breaks down how Lyme and other tick-borne diseases are detected through antibody testing, PCR, tissue analysis, and cutting-edge molecular methods. She explains how her lab discovered multiple new pathogens in the upper Midwest, the role of tick species in disease transmission, and why co-infections complicate diagnosis. This conversation also explores geographic spread, climate change, tick behavior, and the strengths and limitations of today’s test algorithms. Key Topics • Discovery of Borrelia mayonii as a second cause of Lyme disease in the U.S. • Identification and characterization of Ehrlichia muris eauclairensis • Geographic hotspots and why the upper Midwest produces unique pathogens • Tick species differences: blacklegged vs. lone star ticks and their hunting strategies • Co-feeding in ticks and its role in pathogen evolution • Why early Lyme tests often return false-negative results • The science behind false positives and cross-reactivity • PCR advantages and limitations for detecting Borrelia • When skin biopsies can outperform blood tests • Differentiating Lyme, B. miyamotoi, Anaplasma, Babesia, and Powassan virus • When clinicians should order a full tick-borne disease panel • How climate and ecological changes drive new tick-borne threats • The promise of metagenomics and immune-signature diagnostics What You’ll Learn • Why current Lyme testing algorithms struggle in early infection • How new tick-borne pathogens are discovered and validated • Why lone star ticks are more aggressive and changing regional risk • When and why molecular testing is more effective • What symptoms point to co-infections needing additional testing • Why doxycycline is not effective for certain pathogens like Babesia • How metagenomic sequencing could identify every pathogen in a single sample • Where diagnostic innovation is heading and what patients can expect

    1h 51m

  4. 21 FEB

    The Science of Why Some People Don’t Recover from Lyme Disease — Inside the Largest Clinical Study at MIT – with Dr. Michal (Mikki) Tal

    What makes Lyme disease resolve quickly in some people but turn into a life-altering chronic illness in others? In this episode, world-leading immunologist Dr. Michal “Mikki” Tal, Principal Scientist at MIT, explains what her team is discovering through the MAESTRO Study — the largest clinical research project in MIT’s history and the first of its kind to include real Lyme patients in a multi-system biological analysis. Dr. Tal’s work sits at the intersection of immunology, bioengineering, and women’s health, uncovering how infections like Lyme and COVID can cause persistent inflammation, immune miscommunication, and hormonal imbalance. Through MAESTRO, she’s mapping how recovery breaks down — and what can be done to predict, prevent, and ultimately reverse chronic illness. 👩‍🔬 About Dr. Tal Dr. Michal “Mikki” Caspi Tal, PhD Principal Scientist, MIT Department of Biological Engineering Associate Scientific Director, MIT Center for Gynepathology Research Head, Tal Research Group A Yale-trained immunologist (PhD under Dr. Akiko Iwasaki) and former Stanford researcher in Dr. Irving Weissman’s lab, Dr. Tal specializes in infection-associated chronic illnesses. She has received NIH NIAID fellowships and the Bay Area Lyme Foundation Emerging Leader Award for her pioneering research on the immune mechanisms linking Lyme disease, Long COVID, and chronic inflammation. 🧬 What You’ll Learn 1. Why 10% of People Don’t Recover from Lyme Roughly 90% of Lyme patients recover after antibiotic treatment — but 10% continue to experience long-term symptoms. Dr. Tal explains that this is not psychological; it’s biological. In these individuals, the immune system’s “off switch” fails, leading to chronic inflammation, tissue injury, and immune exhaustion — a state she calls catastrophic recovery failure. 2. The MAESTRO Study: Measuring Absolutely Everything MAESTRO (Mucosal And systEmic Signatures Triggered by Responses to infectious Organisms) integrates advanced biology, neuroscience, and patient experience. Participants provide: Blood, saliva, urine, and swab samples for immune and microbiome profiling EEG brainwave tests (WAVi), eye-tracking (RightEye), and cognitive testing (BrainCheck) NASA Lean Test for autonomic dysfunction (POTS) and capillaroscopy to visualize microvascular flow Evie Ring wearable tracking sleep, heart rate, and oxygen Plainly: MAESTRO maps the connection between what patients feel and what’s happening biologically inside their brains, blood, and immune systems. 3. Sex-Based Immunity and Hormonal Differences Every immune cell carries receptors for estrogen, progesterone, and testosterone. These hormones literally change how the immune system responds. Men: more severe acute infections. Women: more likely to survive but develop chronic post-infectious illness. This isn’t “in their heads” — it’s a biological trade-off built into human evolution. 4. Lyme and Reproductive Health Dr. Tal’s group uncovered Borrelia (Lyme bacteria) in the uterus and bladder of infected animal models, and population studies show a twofold increase in gynecologic conditions (like endometriosis and PCOS) after Lyme infection, even post-treatment. This challenges the old view of Lyme as a joint or nerve disease — revealing it as a whole-body infection that can affect reproductive and hormonal health. 5. Immune Checkpoints: How Borrelia Hits the Brakes The immune system uses checkpoint molecules as brakes to avoid self-destruction. Dr. Tal found that Borrelia’s P66 protein can engage SIRP-alpha, a human “stop signal,” effectively telling the immune system to stand down too soon. This immune hijacking may explain persistent infection and the biological differences in recovery between men and women. 6. Collagen, Mast Cells, and Hypermobility Many chronic Lyme patients report joint laxity or Ehlers-Danlos-like symptoms. Dr. Tal’s research shows Borrelia can reside within collagen-rich tissues, provoking mast cells (inflammatory immune cells) to attack both the bacteria and the body’s connective tissue — weakening ligaments, causing pain, and perpetuating inflammation. 7. Allergy-Type Immune Reactions to Bacteria Around one-third of chronic Lyme patients produce IgE antibodies (normally linked to allergies) against Borrelia and oral spirochetes such as Treponema denticola. In simple terms: the immune system becomes “allergic” to its own bacteria, keeping inflammation alive even after infection clears. 8. Brain Biomarkers: Reaction Time and Neuroinflammation By using EEG and eye-tracking technology, the MAESTRO study reveals that people with chronic Lyme and Long COVID have measurably slower reaction times — a neurological signature of inflammation that validates patient-reported “brain fog.” The data prove that cognitive slowdown is not subjective — it’s an objective biomarker of neuroinflammatory illness. 9. Predicting Chronic Illness Before It Happens The ultimate goal: identify the biological patterns that forecast who will develop chronic Lyme. Using multi-omics (proteomics, metabolomics, genomics) integrated with functional tests, Dr. Tal’s team aims to create the first predictive diagnostic framework for infection-associated chronic disease. 🧠 Key Quotes “MAESTRO stands for Measure Absolutely Everything. That’s how we make invisible illness visible.” “Every immune cell listens to hormones. That’s why recovery looks different between men and women.” “Borrelia can tap the immune system’s brakes — that’s how it survives.” “Reaction time is data. It’s what brain fog looks like when you can finally measure it.” 🧩 The Big Picture Dr. Tal’s work bridges hard science and patient reality, validating what millions of Lyme patients have felt for decades. Her data suggest that chronic Lyme disease, Long COVID, and similar conditions share a common root: a failure of immune resolution. By decoding these patterns, her team is paving the way for real diagnostics, targeted treatments, and renewed hope. 🧪 Participate The Tal Research Group's MAESTRO program is seeking Chronic Lyme Disease and Acute Lyme Disease patients to participate in their large clinical study. Participants provide samples and complete neurological and physiological testing at baseline, 6-month, and 12-month visits. Visit Tal Research Group MAESTRO website to learn more or be connected with the MAESTRO research team.

    1h 56m

  5. 14 FEB

    How MIT Is Redefining Chronic Lyme Disease: Inside the MAESTRO Study with Yuri Kim

    In this episode of the Tick Boot Camp Podcast, Matt Sabatello sits down with Yuri Kim, the lead clinical research nurse for MIT’s MAESTRO study, described as one of the largest studies in MIT history focused on Lyme disease and Infection-Associated Chronic Illnesses (IACI). Yuri explains how MAESTRO is collecting deep symptom histories and objective measurements—from eye tracking and EEG/P300 auditory testing to NASA Lean dysautonomia testing, capillaroscopy, and multi-sample biological collection—to identify patterns that validate patient experiences and accelerate real-world clinical understanding. Yuri’s story is equally compelling: she began as an ER nurse in a Level 1 trauma center, transitioned into research nursing (including neurodegenerative and traumatic brain injury work), moved to South Korea during the pandemic, and ultimately joined MIT after a conversation with Dr. Mikki Tal changed the course of her career. Throughout the conversation, Yuri shares what she’s learned from MAESTRO participants: a community often exhausted and dismissed, yet profoundly motivated to help others and drive scientific progress forward. Key Takeaways (Fast Scan) MAESTRO is nearing ~200 participants enrolled, with the chronic Lyme cohort full and enrollment closing soon. The study aims to objectively measure symptoms often dismissed as “anxiety” or “depression,” especially brain fog and dysautonomia. MAESTRO uses multiple cognitive and neurologic measures, including RightEye eye tracking, EEG + P300 auditory “oddball” testing, and remote cognitive battery tests. The team added capillaroscopy (nailfold and toe microvascular imaging) to explore vascular patterns and hemorrhages in chronic illness cohorts. Dysautonomia testing includes NASA Lean Test plus an earpiece device to estimate proxy cerebral blood flow, sometimes showing abnormalities even when vitals look “normal.” Extensive biological sampling (oral, blood, vaginal/rectal) supports proteomics/immune profiling and deeper molecular analysis. Yuri emphasizes: patients’ willingness to participate—despite severe symptoms—is the engine of progress and future change. Detailed Chapter-by-Chapter Show Notes 1) Meet Yuri Kim: The Human Side of Cutting-Edge Lyme Research Matt introduces Yuri as the clinical research nurse leading day-to-day operations of MIT’s MAESTRO study—positioning her as a rare bridge between lab science, clinicians, and patients. Yuri shares that the study is approaching enrollment completion and that the team is eager to analyze a large dataset to “speak up” for participants who have suffered without clear explanations. Highlights: MAESTRO is one of MIT’s largest studies, with enrollment nearing completion. The mission is to transform patient suffering into measurable signals, data, and insight. 2) Yuri’s Background: Pharma, ER Nursing, Research, and Why This Work Became Personal Yuri explains her path: early work as a medical information specialist in pharma (including literature searches and clinician guidance, often involving off-label questions), then an intense period as a Level 1 ER nurse where she witnessed both acute crises and chronic illness desperation. Key insight:Yuri notes that in pharma and ER settings, she repeatedly saw the same reality—patients searching for answers, clinicians constrained by time, and chronic illness voices falling through the cracks. 3) From the ER to Neuro Research: Brain Inflammation, TBI, and the Gap in Chronic Illness Care Yuri left ER work largely due to the physical toll of night shifts and moved into academic research at Boston University. She worked on complex studies involving Alzheimer’s, amyloidosis, and traumatic brain injury. Matt asks whether Lyme came up in those neuro settings. Yuri says no—but now she views neurodegenerative symptoms differently and believes clinicians should consider underlying root causes, including infection. Listener connection:This segment reinforces how often Lyme-related cognitive decline can be misinterpreted or missed when viewed through siloed specialties. 4) Lyme Awareness Outside the U.S.: South Korea, Tick-Borne Illness, and Global Blind Spots During the pandemic, Yuri relocated to South Korea. She shares that Lyme isn’t commonly discussed there, though other tick-borne illnesses exist. Yuri underscores a global concern: agricultural and rural communities face tick exposure without awareness of the chronic implications. 5) How Yuri Joined Dr. Mikki Tal and MAESTRO (And Why She Changed Her Mind) One of the most memorable segments: Yuri reveals she had already accepted another MIT nursing role—but after speaking with Dr. Tal, she pivoted immediately, calling it the best career decision she’s ever made. Why it matters: It shows how MAESTRO is not just a study; it’s a mission-driven effort that attracts top clinical talent. 6) Day One at MAESTRO: Meeting the Severely Ill and the Community’s Unmatched Generosity Yuri recounts a powerful early experience: meeting a participant who was bedbound and profoundly symptomatic, yet eager to contribute anything possible to help the community. Matt connects this to Tick Boot Camp’s origin story: people with minimal energy still showed up to help others. The theme becomes clear—Lyme patients are often depleted but relentlessly generous. What MAESTRO Measures (The Four-Hour Visit Breakdown) 7) Brain Fog: Why MAESTRO Treats It as a Complex Phenomenon Yuri explains MAESTRO’s approach: brain fog isn’t one symptom. It can involve memory, processing speed, visual stimulation sensitivity, pain-triggered cognition changes, and motor response delays. Core idea: MAESTRO attempts to measure brain fog from multiple angles—visual processing, auditory processing, reaction time, and executive function. 8) RightEye Eye Tracking: Visual Stimulus + Reaction Time as Objective Signal Participants complete a structured set of ocular motor tasks (pursuit, saccades) and reaction-time games (shape recognition mapped to numbered inputs). Yuri notes many chronic illness participants struggle even with basic saccades, often aligning with reported visual disturbances. What MAESTRO is measuring: Ocular motor control Visual processing Decision speed Reaction time consistency 9) EEG + P300 “Oddball” Test: Auditory Processing Meets Motor Output Participants wear an EEG cap (19 regions) and listen to tones: common low-pitch and rare high-pitch. They must press the spacebar only for the rare tone. Yuri notes that even a 4-minute test can be exhausting for people with cognitive dysfunction, and participants often describe a frustrating “delay” between knowing what to do and physically doing it. Why this matters: This may help validate cognitive dysfunction even when standard office screening looks normal. 10) Remote Cognitive Battery Testing: Scaling Measurement Beyond MIT Participants complete executive function tests at home (memory, Stroop-like color-word matching, trail-making tasks). Yuri emphasizes why this matters: many patients can’t travel, and symptoms vary dramatically by day, cycle, and crash patterns. Big future direction: Remote testing could expand access to bedbound patients and capture “good day vs bad day” variability. 11) Dysautonomia & POTS: NASA Lean Test + Proxy Cerebral Blood Flow Yuri details NASA Lean testing: supine rest, then standing/leaning while monitoring vitals and symptoms. The standout: sometimes vitals appear stable while patients feel intensely symptomatic—yet the cerebral blood flow proxy measurement fluctuates significantly. Clinical implication discussed: This approach could become a tool for identifying dysautonomia-related issues when standard vitals “look fine.” 12) Capillaroscopy: Nailfold + Toe Microvascular Imaging MAESTRO added capillaroscopy to examine microvascular patterns, including abnormal shapes and possible hemorrhages seen more frequently in chronic cohorts (as her clinical observations suggest). They also measure capillaries pre- and post-NASA Lean to explore whether symptomatic shifts correlate with microvascular changes. Why patients find it meaningful: They can visually see something measurable that aligns with how they feel. 13) Standard Neuro Screening Doesn’t Capture Lyme Brain Fog Yuri shares a crucial point: participants often perform fine on standard screens like the Mini-Mental State Exam, suggesting that infection-associated cognitive dysfunction can be subtle, dynamic, and not detected by traditional tools—reinforcing the need for MAESTRO-style measurement. Biological Samples: “Measure Everything” (Head to Toe) 14) Multi-Sample Collection: Oral, Blood, Vaginal, Rectal Yuri explains the breadth of biological sampling, including saliva/oral samples (cotton chew + gum swab), multiple blood tubes, and sex-specific sampling to explore immune, hormonal, microbiome, and gynecologic dimensions. Why it’s being done: To connect symptom clusters to molecular patterns and explore sex differences in chronic illness response. 15) Storage, Batch Effects, and What Happens After Enrollment Closes Samples are aliquoted and stored at -80°C until they can be processed/shipped in ways that minimize batch effects. The next phase is analysis and collaboration—including proteomics and immune signaling exploration. 16) Giving Back to Participants: The Challenge and the Intention Yuri acknowledges the “fine line” between research-only testing and clinically actionable reporting, but stresses MIT’s intention to return what can be responsibly shared through certified partners—while being careful not to over-interpret research findings. Collaboration, Scaling, and What Comes Next 17) Collaboration Across Institutions: The Missing Platform Matt compares Lyme research needs to cybersecurity threat-sharing between banks: competitors collaborate

    1h 35m

  6. 7 FEB

    The Pioneer Who Pushed Lyme Disease Into the Light — Mary Beth Pfeiffer

    Mary Beth Pfeiffer, the pioneering investigative journalist who transformed national understanding of Lyme disease, joins the Tick Boot Camp Podcast for a landmark conversation. Before her work, Lyme disease was widely dismissed as rare, mild, and easily treated. After her reporting, that narrative collapsed. Through her award-winning journalism and her groundbreaking book Lyme: The First Epidemic of Climate Change, she became the first major voice to expose the truth: Lyme disease is a global, climate-driven epidemic that is chronically misdiagnosed, dangerously underestimated, and systematically mishandled by mainstream medicine. In this interview, Mary Beth shares how her earlier investigative work on mental illness in U.S. jails prepared her to recognize patterns of institutional failure within the Lyme disease system. For decades, she documented how people with bipolar disorder and schizophrenia were misunderstood, punished, or dismissed by the very institutions meant to protect them. When she turned her attention to Lyme in 2012, she immediately recognized the same dynamic: patients with neurological and psychiatric manifestations were told they were anxious, depressed, or “crazy,” rather than infected. Families were blamed, symptoms were minimized, and children were left to suffer. Her background gave her a rare lens into how biological illness becomes mislabeled as psychological and how systems silence the very people who need help. Mary Beth explains how her investigative series for the Poughkeepsie Journal went viral worldwide, surprising even her editors. Her reporting was read in all 50 states and across Europe and Australia, prompting the CDC to contact her directly. She details what she uncovered through Freedom of Information Act requests, including internal emails between NIH and CDC officials referring to patients as “Lyme loonies” and framing the situation as a “war” against advocates. These documents revealed attitudes inside the highest levels of public health that shaped decades of policy, diagnostic guidelines, and patient care. The conversation dives into how a small group of early Lyme researchers defined the disease in the 1980s and then used their influence to control medical journals, shape NIH grant funding, and enforce rigid IDSA treatment guidelines. As Mary Beth explains, these early assumptions—often based on limited data and flawed antibody tests—became dogma. Their conclusions created an ecosystem where only short-course antibiotics were considered acceptable, chronic symptoms were dismissed, and doctors who treated beyond the guidelines were punished by medical boards. The result was a generation of patients abandoned by the system, forced to self-fund care, travel to distant specialists, and in many cases bankrupt themselves in search of answers. Mary Beth discusses how patients became her greatest teachers. She shares emotional stories, including children who lost years of their lives, athletes whose careers were derailed, and an 11-year-old boy misdiagnosed for so long he ended up in a hospital bed in his living room before finally being rescued by Dr. Charles Ray Jones. She describes support groups filled with people who had seen five, ten, or fifteen doctors and were told their symptoms were anxiety, depression, or “anything but Lyme.” The interview covers the scientific evidence supporting Lyme persistence, including animal studies, autopsy tissue findings, and molecular research showing Borrelia surviving standard treatment. Mary Beth explains why the two-tier antibody test has failed generations of patients, why indirect antibody tests are inherently flawed for immune-dysregulated populations, and why the future of accurate diagnosis depends on direct detection methods. She highlights emerging technologies, including promising work by Aces Diagnostics and Researcher Holly Ahern, which may finally offer accurate testing across all stages of infection. The conversation moves into the larger systemic problem: how money, insurance policies, medical boards, industry influence, and journal gatekeeping have shaped what doctors are allowed to do. Mary Beth and the Tick Boot Camp team explore why clinicians who try to help chronic Lyme patients often lose insurance coverage, face board complaints, or have their licenses threatened. They discuss how electronic monitoring, AI systems, and corporate-owned medical practices further restrict doctors from practicing individualized, patient-centered medicine. The second half of the interview focuses on the environmental drivers behind the explosion of Lyme disease. Mary Beth explains how warming temperatures, shorter winters, and ecological fragmentation have created ideal habitats for ticks. She describes how ticks have climbed mountains, expanded into higher latitudes, colonized suburban landscapes, and gained longer active seasons. These environmental changes, combined with human development patterns, have dramatically increased opportunities for exposure. She also addresses public interest in the bioweapons question raised by Chris Newby’s book Bitten, explaining why historical documentation and FOIA evidence convinced her that military tick experiments occurred, even if their impact on today’s epidemic is still unknown. The episode closes with Mary Beth’s reflections on prevention, vigilance, and the psychological cost of losing the innocence of nature. She describes how she now sees fields, forests, and even yards differently and why she teaches her grandchildren to treat nature with both respect and caution. She shares her hope for the future: better diagnostics, more independent research, journalists willing to challenge medical orthodoxy, and a cultural shift that frees doctors to practice real medicine rather than rigid algorithms. This interview is essential listening for anyone affected by Lyme disease, anyone questioning why chronic illness is so often dismissed, and anyone seeking to understand how climate change, medical politics, and investigative journalism intersect in one of the most important health crises of our time.

    1h 47m

  7. 31 JAN

    Childhood Lyme Disease, Medical Gaslighting, The Quiet Epidemic, and Becoming the Doctor She Needed – Julia Bruzzese

    In this powerful and deeply moving episode of the Tick Boot Camp Podcast, we sit down with Julia Bruzzese, a 22-year-old Lyme disease survivor, disability advocate, and future physician whose life was forever changed by an untreated tick bite in childhood. After developing a classic bull’s-eye rash at age 9, Julia went undiagnosed for nearly two years, despite textbook symptoms of Lyme disease. By age 11, she experienced a catastrophic neurological decline that left her paraplegic and wheelchair-bound. Over the next decade, Julia saw more than 100 doctors, endured profound medical gaslighting, and navigated an exhausting journey through antibiotics, IVIG, IV antibiotics, plasmapheresis, stem cells, ozone therapy, and integrative care. Julia’s story became internationally known after a moment with Pope Francis on the JFK airport tarmac went viral in 2015—an event that opened doors to care, advocacy, and awareness. She later became the emotional centerpiece of the award-winning documentary The Quiet Epidemic, appeared at New York Fashion Week as a Lyme disease advocate, and was profiled by renowned journalist Mary Beth Pfeiffer. Today, Julia is finishing her undergraduate degree and has been accepted into medical school, determined to become the kind of doctor she needed when the system failed her. This episode is a masterclass in: Pediatric Lyme disease Medical gaslighting vs. lack of education Clinical diagnosis vs. unreliable testing The patient-doctor relationship Chronic illness, disability, and purpose Why Lyme disease changes lives—and why early treatment matters Childhood Lyme Disease & Missed Diagnosis Tick bite and bull’s-eye rash dismissed at age 9 Two years of worsening symptoms labeled as “growing pains,” viruses, or psychological Why early Lyme treatment saves lives Neurological Collapse & Hospital Trauma Sudden onset of paralysis, vision loss, fevers, hair loss, and weakness at age 11 Over 100 doctors and repeated hospitalizations Being accused of malingering and conversion disorder The devastating impact of medical disbelief on children The Quiet Epidemic Documentary How Julia became the heart of the film at age 12 Why she initially hesitated to share her story The emotional impact of seeing her illness reflected on screen How the documentary helps families explain Lyme disease to others Meeting Pope Francis & Global Awareness How a school principal secured last-minute tickets The Pope walks directly to Julia’s wheelchair The moment that changed everything Media coverage that led to access to lifesaving care Treatment Journey Lyme-literate diagnosis by NP Somer DelSignore Oral and IV antibiotics IVIG (including under-dosing issues) Plasmapheresis POTS, Babesia, Bartonella, and autoimmune complications Stem cell therapy abroad Ozone and integrative protocols Why there is no single silver bullet for Lyme disease The Medical System & Lyme Denial Why doctors often say “it’s all in your head” The difference between malice and lack of training How medical education fails chronic illness patients Fear of insurance companies, lawsuits, and “accepted guidelines” Why Lyme is a clinical diagnosis, not a test result Reframing “Medical Gaslighting” Why anger is understandable—but not always healing How patients and doctors can become better partners Understanding doctors’ limitations without excusing harm Advocacy with clarity, not hostility Disability, Identity & Resilience Navigating life and education as a wheelchair user Accommodations, accessibility, and invisible illness “I have Lyme. I am not Lyme.” Learning when to rest, when to fight, and when to live Becoming the Doctor She Needed Working as a medical assistant and hospital volunteer in a wheelchair Applying to and being accepted into medical school Becoming the first wheelchair-using medical student at her institution Why lived experience belongs in medicine Medical Malpractice Lawsuit Lawsuit filed in NYC (March 2021) against multiple doctors and hospitals Failure to diagnose and treat Lyme disease despite clear evidence Why Lyme malpractice cases are rare—and necessary Seeking accountability, not revenge Purpose, Faith & Meaning From “Why me?” to “Why not me?” How suffering clarified her calling The role of faith, family, and community Why Julia wouldn’t give this journey back—even now Memorable Quotes “I was criminalized as an eleven-year-old child for being sick.” “It actually was in my head—the bacteria was in my brain.” “I have Lyme disease. I am not Lyme disease.” “There is no silver bullet for Lyme. Healing is trial and error.” “I wouldn’t be who I am—or know my purpose—without this journey.” Why This Episode Matters This episode is essential listening for: Parents of children with unexplained symptoms Lyme disease and chronic illness patients Medical professionals and students Advocates fighting for better diagnostics and care Anyone who has ever felt dismissed, unseen, or unheard in healthcare Julia Bruzzese’s story is not just about Lyme disease—it’s about truth, resilience, accountability, and hope.

    1h 53m

  8. 24 JAN

    From Lithuania to Lyme: Dr. Karolina Pras’ Journey Through Mold, Long COVID & Chronic Illness — Tick Boot Camp

    In this powerful episode, Tick Boot Camp Podcast interviews Dr. Karolina Praskeviciute (“Dr. Pras”), a multilingual, European-trained medical doctor who has lived in Lithuania, Hong Kong, London, and the United States, traveled to 89 countries, and now uses her global experience to understand chronic illness from a unique vantage point. Dr. Pras shares her deeply personal story of lifelong unexplained symptoms, childhood mold exposure, a bull’s-eye rash at age 15, and a medical system unequipped to recognize chronic tick-borne illness. After a devastating case of early COVID-19 in February 2020, her immune system collapsed, triggering full-blown Lyme disease, Babesia, Bartonella, tick-borne relapsing fever, MCAS, and Chronic Inflammatory Response Syndrome (CIRS). This conversation bridges both sides of medicine—Western and functional—and explores how chronic illness forced Dr. Pras to reevaluate everything she learned as a third-generation physician. She now brings a rare, dual perspective as both clinician and patient. Key Topics Covered ➤ Growing up in Lithuania: culture, safety, freedom & early mold exposure She describes an independent childhood surrounded by nature—but also living in a poorly insulated home with significant hidden mold that triggered early allergies, stomach pain, nosebleeds, and metallic taste. ➤ Medical school awakening: Why Western medicine failed her symptoms Despite coming from a family of doctors, she noticed early on that conventional medicine couldn’t explain many of her symptoms—and she witnessed firsthand how chronic illness is minimized, dismissed, or mislabeled. ➤ The first tick bite at 15 & the bull’s-eye rash ignored by doctors Despite developing textbook erythema migrans, pediatricians refused treatment. Her mother initiated a short doxycycline course on her own—far too short to prevent chronic Lyme. ➤ Traveling the world & accumulating exposures After living and working across continents, she now believes different strains, microbes, and environmental factors layered into the perfect storm. ➤ Long COVID as the breaking point Like many chronically ill patients, COVID destabilized everything: massive immune dysregulation nonstop inflammation MCAS flares worsening neurological symptoms Lyme and Babesia fully activating ➤ Mold + Lyme + Long COVID = The Perfect Storm Her CIRS diagnosis revealed why she never recovered even after leaving mold exposure—and why immune dysfunction made Lyme treatment far more complex. ➤ Her diagnostic breakthrough with IGeneX After repeated false-negative Western blots, specialty testing finally uncovered: Lyme Babesia Bartonella Tick-borne relapsing fever (TBRF) Immune activation on FISH testing ➤ Treatment: Herbs, LymeStop, detox, keto, and functional medicine Her current regimen includes: Houttuynia (major reduction in joint pain within 1 week) Cryptolepis (powerful antimicrobial requiring slow titration) Custom herbal protocols (single-herb tinctures) HBOT INUSpheresis Light sauna Gentle lymphatic drainage Vagus nerve support Journaling & limbic system retraining Strict ketogenic diet after a 7-day fast dramatically reduced inflammation She also discusses the risks of Botox, fillers, tattoos, and skincare toxins for chronically ill patients. ➤ Nervous system healing as the foundation of recovery She explains why vagus nerve work and limbic retraining may fail if patients are still in toxin exposure (like mold or endotoxins)—a vital distinction rarely discussed. ➤ Becoming a doctor who understands chronic illness from both sides This episode explores: medical defensiveness gaslighting vs unhealthy doctor-patient dynamics why patients must be empowered, not dismissed why doctors also need compassion and realistic expectations how her future clinical practice will integrate empathy, functional medicine, and lived experience Top Quotes From Dr. Pras “I dismissed my own symptoms because I was trained to believe nothing was wrong unless labs proved it.” “Mold was the silent force that weakened my system long before Lyme took over.” “Healing is not linear. Some days it feels like I’m starting over, but I always come back stronger.” “Doctors have tools—but without a healthy doctor-patient relationship, those tools don’t work.” “I can help others now because I know when to push and when to pull back. Lived experience matters.” Where to Find Dr. Karolina Pras Instagram: @drkaromd Email: drkaro@healthkonsultant.com (“consultant” spelled with a K)

    1h 33m
See All (552)

About

The goal of the Tick Boot Camp Podcast is to help people liberate themselves and others from suffering caused by Lyme disease through validation, community building, belief that healing is possible, and modeling success. Listen to our Tick Boot Camp podcast using all major podcast streaming services such as Apple Podcasts, Spotify, and YouTube Music. Our podcast is also integrated with smart home devices, such as Amazon Alexa and Apple TV. Ask your device to "play the Tick Boot Camp Podcast!"

Information

  • Creator
    Matt Sabatello and Rich Johannesen
  • Years Active
    2018 - 2026
  • Episodes
    552
  • Rating
    Clean
  • Copyright
    © Copyright 2025
  • Show Website
    Tick Boot Camp

You Might Also Like